Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cannabis Use Disorder

Cannabis Use Disorder

6 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cannabis Use Disorder

36 trials tracked for Cannabis Use Disorder: 4 in phase 3 or 4 and 1 with published results. The most-cited published study has 6 citations.

36Trials tracked
4Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 10 Phase 1 6 Other / NA 16
  1. Phase 3 N-Acetylcysteine for Youth Cannabis Use Disorder Completed · 6 cited
  2. Phase 4 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed
  3. Phase 4 Effects of Pregnancy-associated Hormones on THC Metabolism in Women Completed
  4. Phase 3 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder Completed
  5. Phase 2 Buspirone, Stress, and Attentional Bias to Marijuana Cues Completed
  6. Phase 2 UH3 Varenicline for Cannabis Use Disorder Completed
Show 30 more trials
  1. Phase 2 Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients Completed
  2. Phase 2 Gabapentin for Bipolar & Cannabis Use Disorders Completed
  3. Phase 2 Effect of Lorcaserin on Cannabis Withdrawal and Self-administration Completed
  4. Phase 2 Impact of Progesterone on Stress Reactivity and Cannabis Use Completed
  5. Phase 2 A Teleheath tDCS Approach to Decrease Cannabis Use Completed
  6. Phase 2 Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence Completed
  7. Phase 2 A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder Completed
  8. Phase 2 Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) Completed
  9. Phase 1 Brain Imaging of Cannabinoid Receptors Completed
  10. Phase 1 Cannabis and Schizophrenia: Self-Medication and Agonist Treatment Completed
  11. Phase 1 Progesterone for Cannabis Withdrawal Completed
  12. Phase 1 Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder Completed
  13. Phase 1 Marijuana Effects on Simulated Driving Performance Completed
  14. Phase 1 Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? Completed
  15. N/A CanCope: Digital Intervention for Coping With Cannabis Craving Completed
  16. N/A Approach Bias Modification for the Treatment of Cannabis Use Disorder Completed
  17. N/A Investigating Two rTMS Strategies to Treat Cannabis Use Disorder Completed
  18. N/A An App to Reduce Cannabis Use Among Emerging Adults Completed
  19. N/A Pilot Trial of Contingency Management for Long-Term Cannabis Abstinence Completed
  20. N/A Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use Completed
  21. N/A Cannabis Edibles Packaging Descriptors Experiment Completed
  22. N/A Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents Completed
  23. N/A Clinical Trial Tobacco Marijuana Completed
  24. N/A Impact of Reduced Cannabis Use on Functional Outcomes Completed
  25. N/A Social Media Intervention for Cannabis Use in Emerging Adults Completed
  26. N/A Reducing Cannabis Use for Sleep Among Adults Using Medical Cannabis Completed
  27. N/A Cannabis Edibles Packaging Imagery Experiment Completed
  28. N/A Pain Research: Innovative Strategies With Marijuana Completed
  29. N/A Impact of Reduced Cannabis Use on Functional Outcomes (R33 Phase) Completed
  30. N/A Stress-Reactivity and Cannabis Use in Cannabis-Using Older Adults Completed

Showing the 36 most-cited and recently-updated of 36 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
19 genome-wide significant loci identify genetic architecture and high correlations with other substance use disorders
Genetics & Precision Medicine Meta-analysis
19 genome-wide significant loci identify genetic architecture and high correlations with other substance use disorders Genes linked to stimulant addiction found in largest study yet
This meta-analysis of 709,369 individuals identifies 19 genome-wide significant loci associated with Stimulant Use Disorder. The study also …
Scientists found 19 genetic regions tied to stimulant addiction, including one linked to obesity. The study of over 700,000 people also show…
medRxiv Jun 11, 2026
High-potency cannabis products are consistently linked to increased risks of psychosis and anxiety symptoms
Psychiatry Sys. Review
High-potency cannabis products are consistently linked to increased risks of psychosis and anxiety symptoms High Potency Cannabis Linked to Increased Risk of Psychosis
This narrative review examines the mental health consequences of contemporary high-potency cannabis use in Europe. The authors synthesize ev…
New research highlights a consistent link between high-potency cannabis products and increased risks of psychosis, anxiety, and panic sympto…
Frontiers Jun 10, 2026
Bidirectional link between cannabis use disorder and major depressive disorder affects over 3 million individuals
Psychiatry Meta-analysis
Bidirectional link between cannabis use disorder and major depressive disorder affects over 3 million individuals Depression and cannabis use disorder often go hand in hand for millions of people
This meta-analysis examines the bidirectional association between cannabis use disorder and major depressive disorder across psychiatric and…
A massive analysis of over 3 million people shows depression and cannabis use disorder are closely linked, with higher rates of each conditi…
Jun 6, 2026
Mini review notes elevated substance use in sexual minority women compared to heterosexual women
Psychiatry Sys. Review
Mini review notes elevated substance use in sexual minority women compared to heterosexual women Substance use is higher among sexual minority women than heterosexual women
This narrative mini review examines substance use patterns in sexual minority women (SMW) versus heterosexual women. The authors synthesize …
A review shows substance use is more common among sexual minority women. Bisexual women face the highest risk. This review highlights the ne…
Frontiers May 7, 2026
Cannabis-involved ED visits increased among US youth during COVID-19 pandemic
Infectious Disease
Cannabis-involved ED visits increased among US youth during COVID-19 pandemic Cannabis-related emergency visits rose among young people during COVID-19 pandemic
A US report found cannabis-involved emergency department visits were higher among persons under 25 during the COVID-19 pandemic period compa…
Emergency visits for cannabis use among young people rose during the COVID-19 pandemic compared to before.
CDC Apr 5, 2026
High-frequency rTMS over left DLPFC associated with reduced cannabis dependence and severity in small CUD study
Psychiatry Cohort
High-frequency rTMS over left DLPFC associated with reduced cannabis dependence and severity in small CUD study Brain stimulation shows promise for reducing cannabis dependence in small study
An open-label randomized study of 18 individuals with moderate to severe cannabis use disorder found high-frequency rTMS over the left DLPFC…
High-frequency brain stimulation reduced cannabis cravings and use frequency for up to a year in a small study of people with moderate to se…
Frontiers Apr 3, 2026

Questions about Cannabis Use Disorder

Are emergency department visits for cannabis higher in youth under 25 during COVID?

Emergency department visits for cannabis involving youth did increase during the COVID-19 pandemic compared to before, with higher potency products likely playing a role.

Full answer →